CA2687154A1 - Composition useful for the prevention of the adverse effect due to the use of ppar-gamma agonists - Google Patents

Composition useful for the prevention of the adverse effect due to the use of ppar-gamma agonists Download PDF

Info

Publication number
CA2687154A1
CA2687154A1 CA002687154A CA2687154A CA2687154A1 CA 2687154 A1 CA2687154 A1 CA 2687154A1 CA 002687154 A CA002687154 A CA 002687154A CA 2687154 A CA2687154 A CA 2687154A CA 2687154 A1 CA2687154 A1 CA 2687154A1
Authority
CA
Canada
Prior art keywords
acid
ppar
group
carnitine
diabetes
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002687154A
Other languages
English (en)
French (fr)
Inventor
Menotti Calvani
Stefania D'iddio
Paola Benatti
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sigma Tau Industrie Farmaceutiche Riunite SpA
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2687154A1 publication Critical patent/CA2687154A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/205—Amine addition salts of organic acids; Inner quaternary ammonium salts, e.g. betaine, carnitine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Diabetes (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Hematology (AREA)
  • Rheumatology (AREA)
  • Obesity (AREA)
  • Child & Adolescent Psychology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Medicinal Preparation (AREA)
CA002687154A 2007-05-24 2008-04-28 Composition useful for the prevention of the adverse effect due to the use of ppar-gamma agonists Abandoned CA2687154A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP07108801.7 2007-05-24
EP07108801 2007-05-24
PCT/EP2008/055171 WO2008141897A1 (en) 2007-05-24 2008-04-28 Composition useful for the prevention of adverse effect due to the use of ppar-gamma agonists

Publications (1)

Publication Number Publication Date
CA2687154A1 true CA2687154A1 (en) 2008-11-27

Family

ID=38668873

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002687154A Abandoned CA2687154A1 (en) 2007-05-24 2008-04-28 Composition useful for the prevention of the adverse effect due to the use of ppar-gamma agonists

Country Status (10)

Country Link
US (1) US20100305204A1 (https=)
EP (1) EP2162127A1 (https=)
JP (1) JP2010527952A (https=)
KR (1) KR20100017460A (https=)
CN (1) CN101677983B (https=)
AU (1) AU2008253134A1 (https=)
BR (1) BRPI0812306A2 (https=)
CA (1) CA2687154A1 (https=)
MX (1) MX2009012429A (https=)
WO (1) WO2008141897A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102940884B (zh) * 2012-11-19 2013-11-06 上海市肿瘤研究所 一种肝癌细胞的抑制剂及其在抑制肿瘤生长方面的应用
KR102072075B1 (ko) * 2018-06-21 2020-01-31 울산과학기술원 TRIM25을 유효성분으로 함유하는 PPARγ 분해용 조성물

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1133010B (it) * 1980-05-15 1986-07-09 Sigma Tau Ind Farmaceuti Metodo terapuetico per il trattamento del diabete mellito a insorgenza giovanile e composizione farmaceutica per tale metodo
IT1263004B (it) * 1992-10-08 1996-07-23 Sigma Tau Ind Farmaceuti Impiego della l-carnitina e acil l-carnitine nel trattamento a lungo termine di pazienti diabetici non insulino-dipendenti.
IT1290801B1 (it) * 1996-07-05 1998-12-11 Mendes Srl Uso della acetil l-carnitina, della isovaleril l-carnitina, della propionil l-carnitina o dei loro sali farmacologicamente accettabili
IT1291113B1 (it) * 1997-03-20 1998-12-29 Sigma Tau Ind Farmaceuti Composizione nutritiva terapeutica per soggetti affetti da diabete mellito
AU2192000A (en) * 1998-12-17 2000-07-03 Mindset Biopharmaceuticals (Usa) Inc. Increasing brain glucose utilization
CN1812988A (zh) * 2003-05-13 2006-08-02 斯索恩有限公司 制备噻唑烷二酮衍生物的方法及其化合物
US20050232911A1 (en) * 2004-04-19 2005-10-20 Schreiber Brian D Prevention and treatment of metabolic abnormalities associated with excess intramyocellular lipid
US20060252670A1 (en) * 2004-10-14 2006-11-09 Intercept Pharmaceuticals Inc. Method of reducing drug-induced adverse side effects in a patient

Also Published As

Publication number Publication date
WO2008141897A1 (en) 2008-11-27
JP2010527952A (ja) 2010-08-19
US20100305204A1 (en) 2010-12-02
EP2162127A1 (en) 2010-03-17
AU2008253134A1 (en) 2008-11-27
CN101677983A (zh) 2010-03-24
KR20100017460A (ko) 2010-02-16
BRPI0812306A2 (pt) 2014-11-25
CN101677983B (zh) 2012-12-26
MX2009012429A (es) 2009-12-09

Similar Documents

Publication Publication Date Title
EP0601001B1 (en) Liquid food product containing 3-guanidinopropionic acid
US20080249168A1 (en) Pharmaceutical composition for gout
JPH06510760A (ja) 代謝障害および代謝の治療法
EA015382B1 (ru) Применение рофлумиласта для лечения сахарного диабета типа 2
WO2008058358A2 (en) Descriptive report of the patent of invention of the medicament 'rosuvastatin + metformin' in combined form for cardiovascular diseases.
WO2008058355A2 (en) Descriptive report of patent of invention of the medicament 'atorvastatin + metformin' in combined form for cardiovascular diseases
JP7451413B2 (ja) 肥満の治療および体重管理のためのｇｌｐ－１組成物
WO2005027661A1 (en) Compositions for the treatment and prevention of diabetes mellitus
US8053472B2 (en) Use of the acetyl L-carnitine in association with the biotin for the treatment of patients with type 2 insulin-resistant diabetes mellitus
US20100305204A1 (en) Composition useful for the prevention of adverse effect due to the use of ppar-gamma agonists
DK2136798T3 (en) Compositions useful in the prevention of type 2 diabetes and complications associated therewith in pre-diabetic patients with insulin resistance
JP5697337B2 (ja) ２型糖尿病の処置に有用な組成物
HK1139038A (en) Composition useful for the prevention of adverse effect due to the use of ppar-gamma agonists
TWI364286B (en) Compositions for diabetes treatment and prophylaxis
JP2002220345A (ja) 脂肪肝改善剤
CN102349923B (zh) L-肉碱和葡萄糖治疗心血管疾病的应用
HK1135030B (en) Composition useful for the treatment of type 2 diabetes
CN106880643A (zh) 用于治疗糖尿病的联合用药及药物组合物

Legal Events

Date Code Title Description
FZDE Discontinued

Effective date: 20140429